Loading stock data…
$0.89-0.03 (-2.78%)
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
Connect Biopharma Holdings Limited in the Healthcare sector is trading at $0.89 with a market capitalization of $109M. Wall Street consensus targets $5.88 (8 analysts), implying a +557.7% move over the next 12 months. The stock is currently near its 52-week low of $0.85, remaining 61.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.77M↑ | $169,000 | $0↓ | $16,000↓ | $48,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.60M↑ | -$19.61M↓ | -$15.53M↑ | -$17.68M↓ | -$13.42M |
| Net Income | -$17.28M↑ | -$19.40M↓ | -$15.11M↑ | -$17.20M↓ | -$12.90M |
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacer...